FindTrial
Sign In

Application value of 18F-FDG PET/CT combined with tumor markers in postoperative recurrence and metastasis of lung cancer

Application value of 18F-FDG PET/CT combined with tumor markers in postoperative recurrence and metastasis of lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600130883
Enrollment
Unknown
Registered
2026-08-26
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrence and metastasis of lung cancer

Interventions

Gold Standard:pathology
Index test:PET/CT
serum tumor markers

Sponsors

Xingtai People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. All patients were pathologically confirmed to have lung cancer before treatment; 2. All patients received surgery or radiotherapy and chemotherapy for at least 3 months; 3. All patients have undergone PET/CT imaging and tumor marker testing; 4. No primary tumor in other sites; 5. Complete clinical and follow-up data.

Exclusion criteria

Exclusion criteria: 1. incomplete materials; 2. Confirmed with a primary tumor in another site; 3. lost track of return visit.

Design outcomes

Primary

MeasureTime frame
Serum tumor marke;SUVmax;Sensitivity;Specificity;accuracy;—

Countries

China

Contacts

Public ContactZongliang Li

Xingtai People's Hospital

13730133835@163.com+86 319 328 6292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026